Ionis (IONS) Director Hayden Michael R Buys 20,000 Shares

What Happened
Hayden Michael R, a director of Ionis Pharmaceuticals, reported open-market purchases of a total 20,000 shares of IONS common stock. On 2026-07-30 he acquired 15,000 shares at a weighted-average price of $53.38 for $800,700, and on 2026-07-31 he acquired 5,000 shares at a weighted-average price of $51.60 for $258,000 — total cash outlay $1,058,700. These were purchases (code P), which are generally viewed as a more bullish signal than sales.

Key Details

• Transaction dates and prices:
  • 2026-07-30: 15,000 shares at weighted avg $53.38 (price range reported $53.00–$53.58) — $800,700 (F1).
  • 2026-07-31: 5,000 shares at weighted avg $51.60 (price range reported $51.45–$51.70) — $258,000 (F3).
• Total acquired: 20,000 shares for $1,058,700.
• Shares owned after the transactions: not specified in the details provided in your summary of the Form 4.
• Notable footnotes:
  • F1/F3: Weighted-average prices reported; purchases occurred in multiple trades within the stated price ranges. The reporting person can provide per-trade breakdowns on request.
  • F2: Some securities are held by Genworks 2 Consulting, Inc.; the reporting person’s spouse has sole voting and investment power over those shares.
• Filing timing: Form 4 was filed 2026-07-31 for transactions on 7/30 and 7/31; the filing appears timely (no late-file flag indicated).

Context
These were straightforward open-market purchases (Form 4 code P). For retail investors, purchases by company directors can be informative since they show the insider buying stock, but filings do not explain motivation. The footnotes indicate purchases happened across multiple trades at slightly varying prices and that some shares are held indirectly through an entity controlled (voting/investment power) by the insider’s spouse.